Systems analysis of protective immune responses to RTS,S malaria vaccination in humans

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 9, 2017, Pages 2425-2430

  Kazmin, Dmitri ^a   Nakaya, Helder I ^b   Lee, Eva K ^c   Johnson, Matthew J ^d   Van Der Most, Robbert ^e   Van Den Berg, Robert A ^f   Ballou, W Ripley ^f   Jongert, Erik ^e   Wille Reece, Ulrike ^g   Ockenhouse, Christian ^g   Aderem, Alan ^h   Zak, Daniel E ^h   Sadoff, Jerald ⁱ   Hendriks, Jenny ⁱ   Wrammert, Jens ^a   Ahmed, Rafi ^a   Pulendran, Bali ^a,j  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Georgia Institute of Technology   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e GSK   (Belgium)

^f GLAXOSMITHKLINE   (United States)

^g Program for Appropriate Technology in Health Malaria Vaccine Initiative   (United States)

^h SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

ⁱ CRUCELL HOLLAND BV   (Netherlands)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Immune; Malaria; Systems biology; Systems vaccinology; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; PROTEIN ANTIBODY; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

ADENOVIRIDAE; ADENOVIRUS 35; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALARIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEM ANALYSIS; SYSTEMS BIOLOGY; T LYMPHOCYTE; VACCINATION; ADAPTIVE IMMUNITY; B LYMPHOCYTE; HUMAN EXPERIMENT; IMMUNOGENICITY; NATURAL KILLER CELL; NORMAL HUMAN; PARASITE IMMUNITY; PLASMA CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOSYNTHESIS; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOLOGY; MALARIA FALCIPARUM; METABOLISM; PARASITOLOGY; PATHOGENICITY; PROCEDURES; SECONDARY IMMUNIZATION; VACCINE IMMUNOGENICITY;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANTIBODIES, PROTOZOAN; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; KILLER CELLS, NATURAL; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 85014171345     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1621489114     Document Type: Article

References (38)

1. World Health Organization (2015) World Malaria Report (World Health Organization, Geneva).
2. Strategic Advisory Group of Experts (2011) Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Wkly Epidemiol Rec 90(50):681-699.
3. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A (2010) From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 6(1):90-96.
4. Casares S, Brumeanu TD, Richie TL (2010) The RTS,S malaria vaccine. Vaccine 28(31):4880-4894.
5. Didierlaurent AM, et al. (2014) Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 193(4):1920-1930.
6. Gordon DM, et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171(6):1576-1585.
7. Kester KE, et al.; RTS,S Vaccine Evaluation Group (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J Infect Dis 200(3):337-346.
8. Agnandji ST, Fernandes JF, Bache EB, Ramharter M (2015) Clinical development of RTS,S/AS malaria vaccine: A systematic review of clinical Phase I-III trials. Future Microbiol 10(10):1553-1578.
9. Bojang KA, et al.; RTS, S Malaria Vaccine Trial Team (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 358(9297):1927-1934.
10. Alonso PL, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364(9443):1411-1420.
11. Bejon P, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359(24):2521-2532.
12. Aponte JJ, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomised controlled phase I/IIb trial. Lancet 370(9598):1543-1551.
13. Abdulla S, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359(24):2533-2544.
14. Agnandji ST, et al.; RTS,S Clinical Trials Partnership (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365(20):1863-1875.
15. The RTS,S Clinical Trial Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988):31-45.
16. RTS,S Clinical Trials Partnership (2014) Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11(7):e1001685.
17. Agnandji ST, et al.; RTS,S Clinical Trials Partnership (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367(24):2284-2295.
18. Ockenhouse CF, et al. (2015) Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naïve adults. PLoS One 10(7):e0131571.
19. + T cell immunity. Science 334(6055):475-480.
20. O'Brien KL, et al. (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15(8):873-875.
21. Stewart VA, et al. (2007) Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75(5):2283-2290.
22. Pulendran B, Li S, Nakaya HI (2010) Systems vaccinology. Immunity 33(4):516-529.
23. Pulendran B (2014) Systems vaccinology: Probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci USA 111(34):12300-12306.
24. Querec TD, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10(1):116-125.
25. Nakaya HI, et al. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12(8):786-795.
26. Gaucher D, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205(13):3119-3131.
27. Schoggins JW, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344):481-485.
28. + T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA 109(50):E3503-E3512.
29. Li S, et al. (2014) Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15(2):195-204.
30. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195):667-671.
31. Lee EK (2007) Large-scale optimization-based classification models in medicine and biology. Ann Biomed Eng 35(6):1095-1109.
32. Vahey MT, et al. (2010) Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. J Infect Dis 201(4):580-589.
33. Rydyznski C, et al. (2015) Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun 6:6375.
34. Filtjens J, et al. (2014) Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development. PLoS One 9(1):e87463.
35. Roland J, et al. (2006) NK cell responses to Plasmodium infection and control of intrahepatic parasite development. J Immunol 177(2):1229-1239.
36. Gonzalez-Aseguinolaza G, et al. (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195(5):617-624.
37. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
38. Roederer M, Nozzi JL, Nason MC (2011) SPICE: Exploration and analysis of postcytometric complex multivariate datasets. Cytometry A 79(2):167-174.